Charles Mowbray

Are you going to #ECTMIH2025 in Hamburg next week?

Our team will be speaking about epidemic and pandemic-prone viruses, neglected tropical diseases #NTDs & female genital #schistosomiasis.

👉Find out more: dndi.org/events/2025/...

#beatNTDs

This open science project has been designed from the outset to ensure equitable, affordable global access for anyone in need.

I am incredibly impressed and proud of the work of our team and many collaborators in bringing forward this exciting new preclinical candidate as a contribution to building pandemic preparedness. Congratulations to everyone who has contributed to and supported this program!

Great news! 🎉

Following an independent expert review, we have formally nominated the broad-spectrum pan-coronavirus antiviral ASAP-0017445 as a pre-clinical drug candidate.

🔗Read the press release here: dndi.org/press-releas...

DNDi 2024 Annual Report Browse our interactive Annual Report to learn how solidarity in science is benefiting the most neglected.

🎉 Our annual report is out! In 2024, we advanced work on 🔬 32 projects, including 16 clinical trials in 7 disease areas, conducted across 🌍 60 sites in 23 countries.

Browse our report to learn how solidarity in science is benefiting the most neglected 👉 bit.ly/4eRbJfq

The @ec.europa.eu’s new Medical Countermeasures Strategy could be a critical tool to support end-to-end R&D specifically as it will support pandemic-prone diseases such as Ebola or dengue. [1/4] 👇

@charlesmowbray.bsky.social @rachaelcrockett.bsky.social @childsmichelle.bsky.social

Exciting and important opportunity for early-career researchers to apply for michelsonprizes.smapply.org for disruptive concepts and inventive processes to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases.

⏰ Only 10 days to go! Apply now to become our next #PatientRepresentative.

We’re looking for someone who can help ensure our programmes and commitments truly reflect the needs of the communities we serve.

📆 4 May 2025
👉 bit.ly/4jvtTVE
📣 Help us spread the word!

We're looking for a new #PatientRepresentative to join our Board and help align our programmes and commitments with the needs of the communities we serve.

🗓️ Apply by 4 May 2025
🔗 Details: bit.ly/dndi-patient...

#PatientCentricity #PatientAdvocacy #GlobalHealth #JoinUs

@drluispizarro.bsky.social

YouTube video by Drugs for Neglected Diseases initiative (DNDi) How patents can serve the common good

Did you know that we can manage patents in a way that serves the public good?
Our Intellectual Property & Access Leader shares why, together with our partners from the @asapdiscovery.bsky.social, we are filing a #patent for a promising new #molecule that we developed together.

shorturl.at/IgL80

Opinion: How patents can serve the common good We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that

'We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that.'

Read our full opinion piece co-authored by Ed Griffen (@griffen-ed.bsky.social) and Pascale Boulet ⤵️

cen.acs.org/pharmaceutic...

Interested in how drugs are discovered? My colleague Fanny Beltran Escudié is explaining more in the latest episode of our Drug Discovery Explained series. Over to you Fanny Beltran Escudié... youtu.be/qAg0osQQqVQ @dndi.org

Listening to the excellent panelists and looking forward to joining the discussion in the workshop later. Its great to have a strong focus on the needs and challenges for pandemic preparedness in Africa and listening to African leaders such as Kelly Chibale.
@dndi.org @ippsecretariat.org

EU medicines agency quits X, moves to Bluesky The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.

www.reuters.com/world/europe...

Climate-sensitive infectious diseases are rising, hitting those with the least access to testing and treatment the hardest. We need science-driven solutions to #EndTheNeglect and ensure no one is left behind. 🌍
🔗 dndi.org/advocacy/con...
#WorldNTDDay #BeatNTDs

Today, we spotlight #FGS, an #NTD caused by a parasitic worm 🪱
In Dec, we decided to start conducting research for this disease, recognizing the urgent need for better treatment.
🔗For more info, see the full carousel here: www.instagram.com/p/DFaaKpzoRs...
#WorldNTDDay #BeatNTDs #EndTheNeglect

An inspiring meeting with the LCI in Hamburg this week provides the perfect lead-in to World NTD Day tomorrow!

#WorldNTDDay #EndTheNeglect #beatNTD

@dndi.org

You can find out more at @dndi.org

Innovation is key to eliminating neglected tropical diseases (NTDs). This #WorldNTDDay, we’re
joining @DNDi to invest in solutions that bring treatments, diagnostics, and hope to affected
communities. #EndTheNeglect #beatNTDs

It is great to have @wellcometrust.bsky.social leadership and partnership in this important work!

YouTube video by Drugs for Neglected Diseases initiative Host-Directed Therapies: Drugs that target the human body – NOT the cause of illness? | Episode 1

and watch a short video by my colleague Fanny Beltran Escudié explaining the concept: Host-Directed Therapies: Drugs that target the human body – NOT the cause of illness?
www.youtube.com/watch?v=P2Xl...

Drug discovery explained: What are host-directed therapies? Learn how scientists are using the most advanced technologies to improve the lives of millions of neglected patients around the world.

You can find an introduction to this topic in our series: Drug discovery explained: What are host-directed therapies? dndi.org/stories/2024...

Charles Mowbray on LinkedIn: Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous… It was a pleasure to work with Andrea Lafleur, Stephane Daffis and Byron Arana on this article published last year in Vaccines MDPI. Leishmaniasis is one of…

Leishmaniasis is one of the diseases where @dndi.org and our partners are exploring the role of Host Directed Therapies. We aim to compliment direct acting antiparasitic and antiviral drugs in tackling complex neglected infectious diseases which affect >1bn people.

www.linkedin.com/posts/charle...

Riding High on New Wave of Renewable Energy Tech - BIZ STREAM | NHK WORLD-JAPAN [On-Site Report: Riding High on New Wave of Renewable Energy Tech] This episode focuses on advances in renewable energy and features a massive lightweight hard sail designed for cargo ships and an ult...

www3.nhk.or.jp/nhkworld/en/...

Very happy to raise awareness of the needs of >1bn people affected by terrible neglected diseases such as #Dengue and to highlight the exciting work we have been doing with our colleagues at #BenevolentAI.

Dengue item is at minutes 9:00-12:30 in AI story from 7:30